Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,647Revenue $M747Net Margin (%)13.0Altman Z-Score17.6
Enterprise Value $M2,428EPS $1.3Operating Margin %21.5Piotroski F-Score6
P/E(ttm)27.9Beneish M-Score-2.7Pre-tax Margin (%)21.4Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %--Quick Ratio5.3Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %13.4Current Ratio5.7Lower Leverage y-yY
Price/Free Cash Flow19.8y-y EBITDA Growth Rate %1.7ROA % (ttm)12.2Higher Current Ratio y-yY
Dividend Yield %--PEG2.1ROE % (ttm)13.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M71.3ROIC % (ttm)18.3Gross Margin Increase y-yN

Gurus Latest Trades with MYGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYGNKen Fisher 2016-03-31 Add$34.12 - $43.16
($37.75)
$ 37.15-2%Add 0.01%89,783
MYGNJoel Greenblatt 2015-12-31 Buy 0.09%$37.77 - $46.16
($42.36)
$ 37.15-12%New holding196,364
MYGNKen Fisher 2015-09-30 Add$30.94 - $41.39
($35.43)
$ 37.155%Add 1.96%89,775
MYGNJoel Greenblatt 2015-03-31 Sold Out -0.16%$32.63 - $39.49
($35.79)
$ 37.154%Sold Out0
MYGNMario Gabelli 2015-03-31 Buy $32.63 - $39.49
($35.79)
$ 37.154%New holding25,000
MYGNKen Fisher 2015-03-31 Reduce$32.63 - $39.49
($35.79)
$ 37.154%Reduce -0.32%88,050
MYGNJoel Greenblatt 2014-12-31 Reduce-0.11%$32.01 - $39.49
($35.44)
$ 37.155%Reduce -34.58%568,865
MYGNKen Fisher 2014-12-31 Buy 0.01%$32.01 - $39.48
($35.39)
$ 37.155%New holding88,333
MYGNJoel Greenblatt 2014-09-30 Reduce-0.12%$35.44 - $40.41
($37.28)
$ 37.15-0%Reduce -22.18%869,531
MYGNFirst Eagle Investment 2014-06-30 Sold Out -0.026%$33.1 - $42.21
($37.11)
$ 37.150%Sold Out0
MYGNThird Avenue Management 2014-03-31 Sold Out -0.13%$20.79 - $38.17
($30.6)
$ 37.1521%Sold Out0
MYGNFirst Eagle Investment 2014-03-31 Buy 0.03%$20.79 - $38.17
($30.6)
$ 37.1521%New holding284,826
MYGNRonald Muhlenkamp 2013-12-31 Sold Out -2.3%$20.79 - $30.65
($25.36)
$ 37.1546%Sold Out0
MYGNJoel Greenblatt 2013-12-31 Add0.18%$20.79 - $30.65
($25.36)
$ 37.1546%Add 36.27%1,316,314
MYGNThird Avenue Management 2013-12-31 Buy 0.13%$20.79 - $30.65
($25.36)
$ 37.1546%New holding328,314
MYGNJoel Greenblatt 2013-09-30 Add0.32%$24.396 - $31.8
($28.51)
$ 37.1530%Add 74.78%965,987
MYGNRonald Muhlenkamp 2013-06-30 Buy 2.7%$24.35 - $34.26
($28.98)
$ 37.1528%New holding481,900
MYGNRon Baron 2013-06-30 Sold Out -0.09%$24.35 - $34.26
($28.98)
$ 37.1528%Sold Out0
MYGNJoel Greenblatt 2013-03-31 Add0.24%$24.19 - $27.68
($25.95)
$ 37.1543%Add 62.99%489,388
MYGNRon Baron 2013-03-31 Buy 0.09%$24.19 - $27.68
($25.95)
$ 37.1543%New holding658,653
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MYGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
King Gary A.Exec. VP International Ops 2016-04-06Sell15,000$39.03-4.82view
King Gary A.Exec. VP International Ops 2016-04-01Sell15,000$38.12-2.54view
GILBERT WALTER PHDDirector 2015-12-11Sell5,000$42.23-12.03view
Phanstiel S. LouiseDirector 2015-12-08Sell5,000$44-15.57view
DREISMANN HEINRICHDirector 2015-11-05Sell60,000$44.44-16.4view
MARSH RICHARD ME.V.P., General Counsel 2015-11-04Sell35,000$44.5-16.52view
King Gary A.Exec. VP International Ops 2015-10-28Sell10,000$42.82-13.24view
LANCHBURY JERRY SChief Scientific Officer 2015-10-28Sell50,962$41.86-11.25view
LANCHBURY JERRY SChief Scientific Officer 2015-10-27Sell24,767$41.8-11.12view
LANCHBURY JERRY SChief Scientific Officer 2015-09-17Sell60,270$39.89-6.87view

Quarterly/Annual Reports about MYGN:

News about MYGN:

Articles On GuruFocus.com
Chuck Royce Reduces Several Positions in 4th Quarter Feb 05 2016 
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 

More From Other Websites
Myriad Genetics (MYGN) Q3 Earnings: A Beat in the Cards? Apr 26 2016
Myriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3 Apr 22 2016
ETF’s with exposure to Myriad Genetics, Inc. : April 21, 2016 Apr 21 2016
Myriad Genetics, Inc. breached its 50 day moving average in a Bearish Manner : MYGN-US : April 20,... Apr 20 2016
What is Going On With These Falling Stocks? Apr 19 2016
Why Myriad Genetics is Getting Crushed Apr 19 2016
Myriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual... Apr 14 2016
Myriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual... Apr 14 2016
Myriad Genetics: Solid Product Suite, Currency Hurts Stock Apr 13 2016
Myriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of... Mar 30 2016
Myriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of... Mar 30 2016
Myriad Genetics Gains on Favorable Cancer Test Trial Data Mar 23 2016
Myriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : March 21,... Mar 21 2016
Myriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and... Mar 21 2016
Myriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and... Mar 21 2016
The Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in... Mar 18 2016
Myriad's myPath Melanoma Positive in Second Validation Trial Mar 16 2016
Myriad Presents Second Pivotal Validation Study for Its myPath® Melanoma Test Mar 15 2016
Myriad Genetics to Present at the Barclays Capital 2016 Global Healthcare Conference Mar 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)